12:00 AM
 | 
Jul 21, 2016
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Tumor necrosis factor receptor superfamily member 11a (RANK; TNFRSF11A; CD265); receptor activator of NF-κB ligand (RANKL; TNFSF11); breast cancer

Cancer

INDICATION: Breast cancer

Patient sample and mouse studies suggest inhibiting RANKL could help treat BRCA1-mutant breast cancer. In tissue samples from breast cancer patients, levels of the RANKL receptor RANK were higher in tumors and adjacent normal breast tissue from patients with BRCA1 mutations than in patients with BRCA2 mutations or wild-type BRCA1 and BRCA2. In breast tissue samples from BRCA1-mutant...

Read the full 295 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >